



T R A N S F O R M

pharmaceuticals, inc.

For more information, please contact:

TransForm Pharmaceuticals, Inc.
Duncan Higsons
781/674-7863

Noonan Russo Presence
Robert Stanislaro
212/845-4268

TRANSFORM APPOINTS SAMUEL SAKS, M.D. TO PRODUCT ADVISORY BOARD

Board to facilitate expansion of TransForm's products effort

Lexington, MA, February 13, 2003 – TransForm Pharmaceuticals Inc. (TransForm) today announced that Samuel R. Saks, M.D., former Group Chairman of ALZA Corporation, has agreed to join TransForm's Product Advisory Board. Dr. Saks is a pharmaceutical and biotechnology industry leader with extensive experience in clinical research, medical affairs and pharmaceutical marketing. A member of ALZA's management team since 1992, Dr. Saks oversaw all aspects of ALZA operations, including technology research, product development, commercial development and manufacturing.

“One of our key goals is to develop and commercialize a proprietary pipeline of new and improved pharmaceutical products. To accomplish this, we must garner the best and most creative talent available,” said Norman Selby, President and CEO of TransForm. “We are delighted that Dr. Saks has agreed to lend his experience and expertise to TransForm. Our Product Advisory Board brings together leaders from a wide range of disciplines to assist us in the evaluation of emerging opportunities and the strategic growth of our product portfolio,” concluded Selby.

“I am pleased to have the opportunity to assist TransForm by joining the Product Advisory Board. In addition to TransForm's exceptional in-house talent, this stellar group of individuals provides scientific, medical and commercial expertise that will be invaluable as TransForm builds its products business,” stated Dr. Saks.

TransForm's Product Development Strategy

TransForm is building a pipeline of proprietary products, in collaboration with partners and independently, by leveraging its high-throughput technology and deep expertise in pharmaceutical form and formulation. The Company generates product opportunities from several sources, including 1) its own "Platform to Products" (P2P) effort; 2) working with pharmaceutical partners to help them salvage challenging drug candidates in their pipeline, and; 3) licensing compounds with unique form and formulation challenges. Form and/or formulation issues can prevent a product from either reaching the market or reaching its full market potential, and are not restricted to any particular therapeutic area. Therefore, the scope of TransForm's potential development candidates is very broad.

TransForm has already achieved impressive initial success with its P2P products effort, in which it makes significant improvements to the form and/or formulation of currently marketed drugs, enabling them to realize enhanced clinical performance (e.g. better bioavailability, faster onset, new indication) and therefore greater commercial potential. P2P accomplishments to date include:

- Novel forms and/or formulations found in 8 of 10 marketed compounds analyzed;
- 21 patents filed on the novel forms and/or formulations of marketed compounds;
- Novel forms and/or formulations advanced into animal studies on 5 compounds, with improved performance compared to the marketed product observed in all cases; and
- Licensing discussions ongoing concerning 3 compounds.

The initial charter of the Product Advisory Board is to advise TransForm on its overall product development strategy and plans for identifying and developing lead compounds. The Board also offers ideas for new products and alliances. In addition to Dr. Saks, TransForm's Product Advisory Board members include:

- **Edward M. Scolnick, M.D.**, Chairman; former President, Merck Research Labs and recognized leader spearheading research and development efforts to bring new pharmaceuticals products to the market
- **Robert Langer, Ph.D.**, Professor of Biomedical & Chemical Engineering, MIT; Chair, FDA Scientific Advisory Board; Co-founder, TransForm Pharmaceuticals, Alkermes, AIR, and several other companies

- **Paul Brooke**, Former Managing Director and Head of Healthcare Research and Strategy, Morgan Stanley
- **Armen Tashjian, M.D.**, Professor of Toxicology, *emeritus*, Harvard School of Public Health; Professor of Biological Chemistry and Molecular Pharmacology, *emeritus*, Harvard Medical School
- **Ian Sanderson**, Managing Director and lead Analyst on Emerging & Midcap Pharmaceutical Companies, S.G. Cowen Securities Corporation
- **Michael Schmertzler**, Managing Director, Credit Suisse First Boston
- **Christopher Walsh, Ph.D.**, Professor of Biological Chemistry & Molecular Pharmacology, Harvard Medical School; Former President, Dana Farber Cancer Institute.

About TransForm

TransForm Pharmaceuticals is reinventing the pharmaceutical industry's approach to form and formulation, with a novel set of high-throughput, automated platform technologies, powered by state-of-the-art informatics and a scientific and managerial team with deep experience in pharmaceuticals. It uses these capabilities to optimize drug form and/or formulations, and increase the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. In R&D, TransForm is working with partners such as Alza Corporation and Lilly, to help them make better candidate selection decisions, and reduce attrition and development time and cost. For later stage and marketed products, TransForm can help partners enhance product life cycle management by rapidly discovering novel forms and/or formulations to potentially improve bioavailability, broaden intellectual property protection and enable new dosage forms and/or combination products.

TransForm is also using these capabilities to develop its own proprietary product portfolio. TransForm, founded in late 1999 with initial technology from Millennium Pharmaceuticals (NASDAQ:MLNM), is a privately held company located in Lexington, MA. For more information visit our website at www.transformpharma.com.

###